Find recruiting clinical trials for RA in the UK � from early-stage DMARDs to advanced biologic and targeted therapies. See where trials fit into your treatment pathway.
Free to use � Live data from ClinicalTrials.gov � Updated daily
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Initial treatment after RA diagnosis � typically methotrexate-based
Standard: Methotrexate, Hydroxychloroquine, Sulfasalazine, or Leflunomide
When conventional DMARDs fail to achieve remission or low disease activity
Standard: TNF inhibitors (Adalimumab, Etanercept), Abatacept, Rituximab, or Tocilizumab
After biologic failure or intolerance � oral targeted therapies
Standard: Tofacitinib, Baricitinib, Upadacitinib, or Filgotinib
Persistent disease activity despite multiple therapies � trials are especially important
Standard: Clinical trial, combination biologic strategies, or novel mechanisms
An autoimmune condition causing chronic joint inflammation. Affects about 400,000 people in the UK. Can cause joint damage, pain, fatigue, and reduced mobility if not treated early and aggressively.
Despite many approved treatments, up to 30% of RA patients don't respond adequately. New therapies targeting different pathways (B cells, T cells, JAK-STAT, IL-6) are constantly being studied.
Modern RA care aims for remission or low disease activity. If your current treatment isn't achieving this, a clinical trial may offer access to next-generation therapies before they're widely available.
Loading trials from ClinicalTrials.gov...
Novel approaches include JAK inhibitors (newer generations), selective JAK1 inhibitors, biologic agents targeting new pathways (anti-TL1A), and biosimilar versions of established biologics increasing treatment options.
Many RA trials allow concurrent Methotrexate as background therapy. Some specifically test adding a new drug to Methotrexate. Check individual trial criteria for background medication requirements.
Biosimilars are highly similar versions of biologic drugs (like biosimilar Adalimumab, Rituximab). They offer the same effectiveness at lower cost. Some trials study switching from originator to biosimilar biologics.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.